
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/509970/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Pathophysiology and risk factors of peripartum cardiomyopathy. Nature Reviews Cardiology, 2022, 19, 555-565.	13.7	21
2	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
3	Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. Cancers, 2022, 14, 983.	3.7	0
4	Loss of vascular endothelial notch signaling promotes spontaneous formation of tertiary lymphoid structures. Nature Communications, 2022, 13, 2022.	12.8	16
5	High prevalence of reduced fertility and use of assisted reproductive technology in a German cohort of patients with peripartum cardiomyopathy. Clinical Research in Cardiology, 2022, , 1.	3.3	1
6	Animal Models of Cardiovascular Complications of Pregnancy. Circulation Research, 2022, 130, 1763-1779.	4.5	10
7	Dissecting the target leukocyte subpopulations of clinically relevant inflammation radiopharmaceuticals. Journal of Nuclear Cardiology, 2021, 28, 1636-1645.	2.1	32
8	What needs to be known about longer-term management and prognosis?. , 2021, , 45-65.		0
9	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure. 2021. 23. 527-540.	7.1	37
10	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation, 2021, 143, 1852-1862.	1.6	65
11	Perhexiline treatment improves toxic effects of βâ€adrenergic receptor stimulation in experimental peripartum cardiomyopathy. ESC Heart Failure, 2021, 8, 3375-3381.	3.1	5
12	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clinical and Translational Gastroenterology, 2021, 12, e00371.	2.5	6
13	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e006898.	3.9	12
14	Peripartum cardiomyopathy: from genetics to management. European Heart Journal, 2021, 42, 3094-3102.	2.2	39
15	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 2021, 16, e0255335.	2.5	48
16	Etiology and pathophysiology. , 2021, , 1-11.		1
17	Anthracycline-free tumor elimination in mice leads toÂfunctional and molecular cardiac recovery from cancer-induced alterations in contrast to long-lasting doxorubicin treatment effects. Basic Research in Cardiology, 2021, 116, 61.	5.9	11
18	Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 173-182.	1.0	43

#	Article	IF	CITATIONS
19	Peripartum cardiomyopathy: basic mechanisms and hope for new therapies. Cardiovascular Research, 2020, 116, 520-531.	3.8	33
20	Modulation of cardiac AKT and STAT3 signalling in preclinical cancer models and their impact on the heart. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118519.	4.1	17
21	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovascular Research, 2020, 116, 1875-1886.	3.8	20
22	Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages. Basic Research in Cardiology, 2020, 115, 62.	5.9	41
23	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	2.2	101
24	Assessment of major mental disorders in a German peripartum cardiomyopathy cohort. ESC Heart Failure, 2020, 7, 4394-4398.	3.1	20
25	Human iPSC-Derived Cardiomyocytes of Peripartum Patients With Cardiomyopathy Reveal Aberrant Regulation of Lipid Metabolism. Circulation, 2020, 142, 2288-2291.	1.6	8
26	Effects of six month personalized endurance training on work ability in middle-aged sedentary women: a secondary analysis of a randomized controlled trial. Journal of Occupational Medicine and Toxicology, 2020, 15, 8.	2.2	5
27	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clinical Research in Cardiology, 2020, 109, 1197-1222.	3.3	71
28	Employers With Metabolic Syndrome and Increased Depression/Anxiety Severity Profit Most From Structured Exercise Intervention for Work Ability and Quality of Life Frontiers in Psychiatry, 2020, 11, 562.	2.6	11
29	Common genetic predisposition for heart failure and cancer. Herz, 2020, 45, 632-636.	1.1	16
30	Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers. ESC Heart Failure, 2020, 7, 512-522.	3.1	18
31	miRâ^'21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 1118.	2.4	18
32	Increased prostaglandin-D2 in male STAT3-deficient hearts shifts cardiac progenitor cells from endothelial to white adipocyte differentiation. PLoS Biology, 2020, 18, e3000739.	5.6	3
33	Natriuretic Peptide Receptor 1, a Novel Player in Peripartum Heart Failure. Circulation, 2020, 141, 589-591.	1.6	0
34	Title is missing!. , 2020, 18, e3000739.		0
35	Title is missing!. , 2020, 18, e3000739.		0
36	Title is missing!. , 2020, 18, e3000739.		0

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 18, e3000739.		0
38	Title is missing!. , 2020, 18, e3000739.		0
39	Title is missing!. , 2020, 18, e3000739.		0
40	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clinical Research in Cardiology, 2019, 108, 290-297.	3.3	29
41	Data on left ventricular expression of STAT3 and AKT in transgenic mouse models with B16F10 melanoma. Data in Brief, 2019, 26, 104508.	1.0	1
42	Fluoxetine induces glucose uptake and modifies glucose transporter palmitoylation in human peripheral blood mononuclear cells. Expert Opinion on Therapeutic Targets, 2019, 23, 883-891.	3.4	15
43	Longâ€ŧerm followâ€up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular coâ€morbidities. European Journal of Heart Failure, 2019, 21, 1534-1542.	7.1	51
44	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223
45	Telemonitoring-supported exercise training, metabolic syndrome severity, and work ability in company employees: a randomised controlled trial. Lancet Public Health, The, 2019, 4, e343-e352.	10.0	34
46	Letter by Hilfiker-Kleiner et al Regarding Article, "Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes― Circulation, 2019, 139, e990-e991.	1.6	0
47	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women. European Journal of Preventive Cardiology, 2019, 26, 1903-1906.	1.8	14
48	Comorbidities and Co-Existing Conditions in Heart Failure Around Pregnancy. Cardiovascular Medicine, 2019, , 63-70.	0.0	0
49	Future cardiovascular risk prediction in women with pregnancy complications: the HUNT is on. European Heart Journal, 2019, 40, 1121-1123.	2.2	3
50	Late onset heart failure after childhood chemotherapy. European Heart Journal, 2019, 40, 798-800.	2.2	18
51	Breastfeeding in Patients With HeartÂFailure. JACC Basic To Translational Science, 2019, 4, 866-867.	4.1	1
52	Increased Cancer Prevalence in Peripartum Cardiomyopathy. JACC: CardioOncology, 2019, 1, 196-205.	4.0	30
53	Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase. PLoS ONE, 2019, 14, e0225977.	2.5	4
54	Sex differences in heart failure. European Heart Journal, 2019, 40, 3859-3868c.	2.2	406

#	Article	IF	CITATIONS
55	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia, 2019, 33, 1313-1323.	7.2	20
56	Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing. Hypertension, 2019, 73, 102-111.	2.7	38
57	Cardiology and cardiovascular research in Germany: 5Âyears of gender demographics. Clinical Research in Cardiology, 2019, 108, 218-220.	3.3	3
58	Electrophysiological abnormalities in induced pluripotent stem cellâ€derived cardiomyocytes generated from Duchenne muscular dystrophy patients. Journal of Cellular and Molecular Medicine, 2019, 23, 2125-2135.	3.6	39
59	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
60	Editorial commentary: Peripartum cardiomyopathy: Long-term implications of treatment and management. Trends in Cardiovascular Medicine, 2019, 29, 174-175.	4.9	0
61	Longâ€term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2018, 20, 951-962.	7.1	101
62	A positive feedback loop between IL-1β, LPS and NEU1 may promote atherosclerosis by enhancing a pro-inflammatory state in monocytes and macrophages. Vascular Pharmacology, 2018, 103-105, 16-28.	2.1	59
63	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	7.1	118
64	Regulation and function of endothelial glycocalyx layer in vascular diseases. Vascular Pharmacology, 2018, 100, 26-33.	2.1	128
65	Pregnancy and Heart Disease: Pregnancy-Associated Hypertension and Peripartum Cardiomyopathy. Current Problems in Cardiology, 2018, 43, 364-388.	2.4	15
66	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	7.1	81
67	Cardiomyopathies and Congenital Heart Disease in Pregnancy. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1256-1261.	1.8	2
68	miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo. PLoS ONE, 2018, 13, e0204942.	2.5	4
69	Bromocriptine for the Treatment of Peripartum Cardiomyopathy. Cardiac Failure Review, 2018, 4, 1.	3.0	18
70	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1287-1303.	3.8	91
71	Reply to â€~Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a nationwide Danish cohort'. European Heart Journal, 2018, 39, 3478-3478.	2.2	2
72	Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models. Blood, 2018, 132, 4025-4025.	1.4	0

DENISE HILFIKER-KLEINER

#	Article	IF	CITATIONS
73	Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy. European Heart Journal, 2017, 38, ehw086.	2.2	87
74	Olanzapine and aripiprazole differentially affect glucose uptake and energy metabolism in human mononuclear blood cells. Journal of Psychiatric Research, 2017, 88, 18-27.	3.1	12
75	Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovascular Research, 2017, 113, cvw245.	3.8	23
76	Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>). European Journal of Heart Failure, 2017, 19, 1131-1141.	7.1	163
77	Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. European Journal of Heart Failure, 2017, 19, 1723-1728.	7.1	88
78	Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clinical Research in Cardiology, 2017, 106, 582-589.	3.3	67
79	Myofilament Remodeling and Function Is More Impaired in Peripartum Cardiomyopathy Compared with Dilated Cardiomyopathy and Ischemic Heart Disease. American Journal of Pathology, 2017, 187, 2645-2658.	3.8	35
80	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal, 2017, 38, 2671-2679.	2.2	243
81	Complete recovery of fulminant peripartum cardiomyopathy on mechanical circulatory support combined with highâ€dose bromocriptine therapy. ESC Heart Failure, 2017, 4, 641-644.	3.1	13
82	cUMP hydrolysis by PDE3A. Naunyn-Schmiedeberg's Archives of Pharmacology, 2017, 390, 269-280.	3.0	7
83	Dnmt3a-mediated inhibition of Wnt in cardiac progenitor cells improves differentiation and remote remodeling after infarction. JCI Insight, 2017, 2, .	5.0	12
84	Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression. JCI Insight, 2017, 2, .	5.0	37
85	Cardiomyopathies in Women. , 2017, , 127-139.		0
86	Cardiomyocytes display low mitochondrial priming and are highly resistant toward cytotoxic T ell killing. European Journal of Immunology, 2016, 46, 1415-1426.	2.9	6
87	Mental disorders in adults with congenital heart disease: Unmet needs and impact on quality of life. Journal of Affective Disorders, 2016, 204, 180-186.	4.1	93
88	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. International Journal of Cardiology, 2016, 216, 165-167.	1.7	34
89	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation, 2016, 134, 1973-1990.	1.6	46
90	Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2016, 18, 1096-1105.	7.1	160

DENISE HILFIKER-KLEINER

#	Article	IF	CITATIONS
91	Comparison of the American PPCM RegistryÂData With International Registries. Journal of the American College of Cardiology, 2016, 67, 733-734.	2.8	0
92	Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. New England Journal of Medicine, 2016, 374, 233-241.	27.0	432
93	In vitro maturation of large-scale cardiac patches based on a perfusable starter matrix by cyclic mechanical stimulation. Acta Biomaterialia, 2016, 30, 177-187.	8.3	50
94	Stable Silencing of RUNX1/ETO Induces Expression of a Shortened PU.1 Variant in t(8;21) Kasumi Cells. Blood, 2016, 128, 2716-2716.	1.4	0
95	Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Failure, 2015, 2, 139-149.	3.1	62
96	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. Clinical Research in Cardiology, 2015, 104, 911-917.	3.3	55
97	Peripartum cardiomyopathy: current management and future perspectives. European Heart Journal, 2015, 36, 1090-1097.	2.2	196
98	Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovascular Research, 2015, 106, 365-374.	3.8	80
99	Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. Nature Medicine, 2015, 21, 601-609.	30.7	100
100	Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy. Basic Research in Cardiology, 2015, 110, 60.	5.9	51
101	Schwangerschaftsassoziierte Kardiomyopathie. , 2015, , 1-13.		0
102	Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function—value of the wearable cardioverter/defibrillator. European Journal of Heart Failure, 2014, 16, 1331-1336.	7.1	121
103	Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovascular Research, 2014, 101, 587-596.	3.8	73
104	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	2.2	167
105	<scp>EURObservational</scp> Research Programme: a worldwide registry on peripartum cardiomyopathy (<scp>PPCM</scp>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <scp>PPCM</scp> . European Journal of Heart Failure. 2014. 16. 583-591.	7.1	99
106	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal, 2014, 35, 2165-2173.	2.2	159
107	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	7.1	90
108	Pathophysiology and epidemiology of peripartum cardiomyopathy. Nature Reviews Cardiology, 2014, 11, 364-370.	13.7	194

#	Article	IF	CITATIONS
109	oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. Journal of Molecular and Cellular Cardiology, 2014, 66, 72-82.	1.9	89
110	Improvement of biological age by physical activity. International Journal of Cardiology, 2014, 176, 1187-1189.	1.7	32
111	Focus on pregnancy-mediated heart and vascular disease. Cardiovascular Research, 2014, 101, 543-544.	3.8	4
112	Expression of fibulin-6 in failing hearts and its role for cardiac fibroblast migration. Cardiovascular Research, 2014, 103, 509-520.	3.8	25
113	Small molecule-mediated refolding and activation of myosin motor function. ELife, 2014, 3, e01603.	6.0	47
114	STAT3, a key regulator of cell-to-cell communication in the heart. Cardiovascular Research, 2014, 102, 281-289.	3.8	84
115	Cardiovascular Disorders in Pregnancy: Diagnosis and Management. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2013, 27, 821-834.	2.8	14
116	Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Research in Cardiology, 2013, 108, 366.	5.9	266
117	Article Commentary: Acute Heart Failure: Is it Peripartum Cardiomyopathy or Not?. Obstetric Medicine, 2013, 6, 42-44.	1.1	1
118	Peripartum cardiomyopathy. Current Opinion in Critical Care, 2013, 19, 397-403.	3.2	10
119	Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart, 2013, 99, 308-313.	2.9	121
120	The STAT3 Pathway and Downstream Mechanisms in Cardiac Remodeling: Friend or Foe. , 2013, , 347-364.		1
121	MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. Journal of Clinical Investigation, 2013, 123, 2143-2154.	8.2	400
122	Mirâ^1⁄417-92 Identifies BCL2 As a Therapeutic Target In BCR-ABL Positive B-Lineage Acute Lymphoblastic Leukemia. Blood, 2013, 122, 835-835.	1.4	0
123	Protective Function of STAT3 in CVB3-Induced Myocarditis. Cardiology Research and Practice, 2012, 2012, 1-11.	1.1	20
124	STAT3 regulation of and by microRNAs in development and disease. Jak-stat, 2012, 1, 143-150.	2.2	32
125	Circulating microparticles as indicators of peripartum cardiomyopathy. European Heart Journal, 2012, 33, 1469-1479.	2.2	56
126	Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature, 2012, 485, 333-338.	27.8	450

#	Article	IF	CITATIONS
127	16-kDa Prolactin and Bromocriptine in Postpartum Cardiomyopathy. Current Heart Failure Reports, 2012, 9, 174-182.	3.3	42
128	Nebivolol Exerts Beneficial Effects on Endothelial Function, Early Endothelial Progenitor Cells, Myocardial Neovascularization, and Left Ventricular Dysfunction Early After Myocardial Infarction Beyond Conventional β1-Blockade. Journal of the American College of Cardiology, 2011, 57, 601-611.	2.8	111
129	Long-term outcome of Peripartum cardiomyopathy in a population with high seropositivity for Human Immunodeficiency Virus. International Journal of Cardiology, 2011, 147, 202-208.	1.7	75
130	Erythropoietin Preserves the Endothelial Differentiation Capacity of Cardiac Progenitor Cells and Reduces Heart Failure during Anticancer Therapies. Cell Stem Cell, 2011, 9, 131-143.	11.1	68
131	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197.	2.2	1,694
132	STAT3 and cardiac remodeling. Heart Failure Reviews, 2011, 16, 35-47.	3.9	84
133	Left bundle branch block during pregnancy as a sign of imminent peripartum cardiomyopathy. European Heart Journal, 2011, 32, 1076-1076.	2.2	8
134	Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. European Heart Journal, 2011, 32, 1287-1297.	2.2	119
135	Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy. Oncotarget, 2011, 2, 825-825.	1.8	1
136	Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart, 2010, 96, 1352-1357.	2.9	47
137	Continuous Glycoprotein-130–Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction. Circulation, 2010, 122, 145-155.	1.6	140
138	Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports. Journal of Medical Case Reports, 2010, 4, 80.	0.8	31
139	Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum Cardiomyopathy. Circulation, 2010, 121, 1465-1473.	1.6	429
140	Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2010, 12, 767-778.	7.1	787
141	Peripartum Cardiomyopathy: Role of STAT-3 and Reactive Oxygen Species. , 2010, , 317-337.		Ο
142	Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiology, 2009, 5, 175-189.	1.2	47
143	Management of peripartum cardiomyopathy. Current Heart Failure Reports, 2008, 5, 238-244.	3.3	12
144	Peripartum cardiomyopathy—a new treatment option by inhibition of prolactin secretion. American Journal of Obstetrics and Gynecology, 2008, 199, e5-e6.	1.3	58

#	Article	IF	CITATIONS
145	The myocardial JAK/STAT pathway: From protection to failure. , 2008, 120, 172-185.		304
146	Peripartum Cardiomyopathy: Recent Insights in its Pathophysiology. Trends in Cardiovascular Medicine, 2008, 18, 173-179.	4.9	90
147	Cardioprotection by Ischemic Postconditioning Is Lost in Aged and STAT3-Deficient Mice. Circulation Research, 2008, 102, 131-135.	4.5	257
148	Reversal of IFNâ€Ĵ³, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. European Journal of Heart Failure, 2008, 10, 861-868.	7.1	162
149	Disease-Modifying Mutations in Familial Hypertrophic Cardiomyopathy. Circulation, 2008, 117, 1775-1777.	1.6	10
150	Postpartum Cardiomyopathy. Deutsches Ärzteblatt International, 2008, 105, 751-6.	0.9	17
151	MYOCARDIAL AUTOANTIBODIES AND THEIR CLINICAL SIGNIFICANCE. , 2007, , 355-365.		1
152	A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy. Cell, 2007, 128, 589-600.	28.9	736
153	Recovery From Postpartum Cardiomyopathy in 2 Patients by Blocking Prolactin Release With Bromocriptine. Journal of the American College of Cardiology, 2007, 50, 2354-2355.	2.8	103
154	Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Research in Cardiology, 2007, 102, 393-411.	5.9	172
155	Molecular Mechanisms in Heart Failure. Journal of the American College of Cardiology, 2006, 48, A56-A66.	2.8	118
156	Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. European Heart Journal, 2006, 27, 441-446.	2.2	273
157	JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. Cardiovascular Research, 2006, 71, 108-117.	3.8	35
158	Preclinical Testing of Tissue-Engineered Heart Valves Re-Endothelialized Under Simulated Physiological Conditions. Circulation, 2006, 114, 1559-65.	1.6	115
159	STAT3-Mediated Activation of Myocardial Capillary Growth. Trends in Cardiovascular Medicine, 2005, 15, 152-157.	4.9	58
160	Many good reasons to have STAT3 in the heart. , 2005, 107, 131-137.		99
161	Lack of JunD Promotes Pressure Overload–Induced Apoptosis, Hypertrophic Growth, and Angiogenesis in the Heart. Circulation, 2005, 112, 1470-1477.	1.6	60
162	Increased Collagen Deposition and Diastolic Dysfunction but Preserved Myocardial Hypertrophy After Pressure Overload in Mice Lacking PKCε. Circulation Research, 2005, 96, 748-755.	4.5	81

#	Article	IF	CITATIONS
163	Signal Transducer and Activator of Transcription 3 Is Required for Myocardial Capillary Growth, Control of Interstitial Matrix Deposition, and Heart Protection From Ischemic Injury. Circulation Research, 2004, 95, 187-195.	4.5	345
164	Regulation of Proangiogenic Factor CCN1 in Cardiac Muscle. Circulation, 2004, 109, 2227-2233.	1.6	104
165	Allopurinol Attenuates Left Ventricular Remodeling and Dysfunction After Experimental Myocardial Infarction. Circulation, 2004, 110, 2175-2179.	1.6	188
166	Alterations in Janus Kinase (JAK)-Signal Transducers and Activators of Transcription (STAT) Signaling in Patients With End-Stage Dilated Cardiomyopathy. Circulation, 2003, 107, 798-802.	1.6	135
167	Role of interleukinâ€6 for left ventricular remodeling and survival after experimental myocardial infarction. FASEB Journal, 2003, 17, 1-20.	0.5	113
168	Expression of CYR61, an Angiogenic Immediate Early Gene, in Arteriosclerosis and Its Regulation by Angiotensin II. Circulation, 2002, 106, 254-260.	1.6	103
169	TNFα decreases αMHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation. Cardiovascular Research, 2002, 53, 460-469.	3.8	11
170	Role of NAD(P)H Oxidase in Angiotensin Il–Induced JAK/STAT Signaling and Cytokine Induction. Circulation Research, 2000, 87, 1195-1201.	4.5	256
171	Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques. Circulation, 2000, 101, 1372-1378.	1.6	608